Targeted Therapy and Checkpoint Immunotherapy in Lung Cancer

This article discusses the molecular characteristics of the main lung cancer subtypes and discusses the current guidelines and novel targeted therapies, including checkpoint immunotherapy.
Source: Surgical Pathology Clinics - Category: Pathology Authors: Source Type: research

Related Links:

This article discusses the molecular characteristics of the main lung cancer subtypes and discusses the current guidelines and novel targeted therapies, including checkpoint immunotherapy. PMID: 32005431 [PubMed - in process]
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Tags: Surg Pathol Clin Source Type: research
ins I Abstract Allogeneic cancer cell lines serve as universal source of tumor-associated antigens in cancer vaccines. Immunogenic high hydrostatic pressure-killed cancer cells derived from cell lines can be used for the generation of dendritic cell (DC)-based active cellular immunotherapy of non-small cell lung cancer (NSCLC). We investigated the expression of 12 known NSCLC tumor-associated antigens (TAA) (CEA, MAGE-A1, MAGE-A3, MAGE-A4, PRAME, hTERT, HER2, MUC1, Survivin, STEAP1, SOX2 and NY-ESO-1) in 6 NSCLC cell lines as candidates for the generation of DC-based lung cancer vaccine. We showed that the selecte...
Source: Immunology Letters - Category: Allergy & Immunology Authors: Tags: Immunol Lett Source Type: research
Aim: To compare survival outcomes in patients with non-small cell lung cancer (NSCLC) treated with modern-era drugs (antifolates, antiangiogenics, tyrosine kinase and anaplastic lymphoma kinase inhibitors, immunotherapy) with treatment initiation in 2011-12 and 2015-16, respectively. Patients and Methods: Prospective data from Czech TULUNG Registry (960 patients from 2011-12 and 512 patients from 2015-16) were analyzed. Kaplan-Meier analysis was used to estimate overall survival (OS) and progression-free survival (PFS); Cox proportional hazards model to assess factors associated with 2-year survival. Results: Survival at 2...
Source: In Vivo - Category: Research Authors: Tags: Clinical Studies Source Type: research
In this study, we investigated genetic variations in EGFR and their association with the clinical and pathological factors of NSCLC. MATERIAL AND METHODS Clinical cases (331 patients) and The Cancer Genome Atlas (TCGA) cases (1040 patients) were selected and analyzed using the refractory mutation systems cBioPortal and the Tumor Immune Estimation Resource (TIMER). RESULTS EGFR mutation frequencies were 54.4% (180 of 331 patients) and 8.0% (83 of 1040 patients) in the clinical and TCGA cohorts, respectively. EGFR mutations were strongly associated with smoking and pathology (P≤0.05) in the clinical cohort, and with gende...
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
Conclusion: Bronchoscopic re-biopsy for progressive lung cancer is feasible and safe. Histological change can be detected in a considerable number of patients, which is potentially valuable information for guidance of subsequent treatment.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung cancer Source Type: research
Nowadays, cancer immunotherapy is rapidly evolving and monoclonal antibodies targeting the programmed death-1 receptor (PD-1)/PD ligand 1 (PD-L1) pathway have been approved for the treatment of NSCLC; however, there is lack of evidence regarding the current use of PD-L1 analysis in the everyday clinical practice.For this purpose we conducted a retrospective observational study in our lung cancer oncology unit. Eligible patients were adults of both sexes with non-small cell lung cancer who were treated in our department from April 2017 through December 2018. In total 123 patients were investigated regarding PD-L1 expression...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung cancer Source Type: research
Introduction: The EBUS-TBNA is a minimally invasive technique widely used in the diagnosis, staging and immunohistochemistry analysis of lung cancer.1PDL-1 is a checkpoint on NSCLC that can be targeted with immunotherapy.2Routine PDL-1 testing was introduced at Oxford University Hospital NHS Foundation Trust (OUHFT) in 2017 and it is unclear if EBUS-TBNA provides adequate tissue for testing. In our current practice at the OUHFT, all NSCLC cases (Squamous Cell Lung Carcinoma and Lung Adenocarcinoma) identified on cytopathology are subsequently tested for PDL-1 tumour percentage score (TPS). The aim of this study was to see ...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung cancer Source Type: research
Conclusion: These data suggests that antibiotics may reduce effectiveness of IO in lung cancer patients when prescribed up to three months before initiation of treatment. The authors intend to underscore the importance of prescribing antibiotics in lung cancer patients only when strictly necessary, especially if IO is a therapeutic option.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung cancer Source Type: research
Introduction: Treatment of Non-small Cell Lung Cancer (NSCLC) underwent notable evolution during the last 15 years. New drugs have been introduced, including pemetrexed, biologicals and immunotherapy, resulting in improvement of outcomes.Aims: We aimed to compare the probability of 2-year survival (2YS) between patients with NSCLC treated in years 2011-12 and 2015-16 and analyze the factors associated with higher probability of 2YS.Methods: Prospective data from the Czech TULUNG registry (a multicenter registry of NSCLC patients treated with personalized treatments) were used. We compared the data of NSCLC patients that st...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung cancer Source Type: research
ConclusionsWe discover prominent and distinct associations between TIBs antibody isotypes and survival in lung adenocarcinoma carrying specific driver mutations. These findings indicate that particular types of tumor-immunity relations could be beneficial in particular driver mutation context, which should be taken into account in developing strategies of cancer immunotherapy and combination therapies. Specificity of protective B cell populations in specific cancer subgroups could become a clue to efficient targeted immunotherapies for appropriate cohorts of patients.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Carcinoma | Genetics | Immunotherapy | Lung Cancer | Pathology